Opicapon Capsules, was officially accepted by CDE, and now the import application has also been accepted. With the introduction of this Opicapon capsule by Fosun Pharma and its application for market launch in China, it means that it is expected to benefit...
Best Practices, LLC's excellence services uncovers field research highlighting benchmark insights from leading companies excelling in product launch, brand management, product planning, market research and many other functions.
A new pharma launch paradigm: From one size fits all to a tailored product approachMichael KunstLoic Plantevin
Dr. Wang Haibin, CEO of BioRay, said: "We are delighted to collaborate with UCB, a global leader in developing novel medicines for immunological diseases. Bimzelx®is a unique and innovative product in addressing the pressing need for new treatment solutions. With ...
We’ve seen several examples in recent years of pharma companies relying on skewed market forecasts. In one, the manufacturer failed to understand the amount of pent-up prevalent demand for a product, as well as the number of patients that would switch from other therapies due to a complicated...
Said Andy Farrant, General Manager of Luye Pharma Ltd: “We are incredibly excited about the launch of Zeyzelf®twice weekly, as it marks a new treatment option for Alzheimer's dementia, a disease which is set to affect 1 million people in the next two years. There have been very few...
To become a key area in nurturing new quality productive forces in northern China, Yantai will upgrade traditional industries, develop strategic emerging industries, and seize opportunities in future industrial development. In the field of biomedicine, Yantai is leveraging the Blue Pharma Valley to beco...
Well, not everyone. There’s been a strange and uncomfortable silence from a major player in American health care – the insurance companies. While “Big Pharma” regularly face the wrath of pundits and politicians, “Big Payor” seems to get a pass. And it’s not unreasonable to conclude ...
We’ve seen several examples in recent years of pharma companies relying on skewed market forecasts. In one, the manufacturer failed to understand the amount of pent-up prevalent demand for a product, as well as the number of patients that would switch from other therapies due to a complicated...
"In the first half of 2022, despite the pressure arising from Covid-19 resurgence in various regions of China, Fosun Pharma continued to promote innovation and transformation, comprehensively accelerated its international layout, strengthened the product pipelines, promoted the integration of operation, ...